FOLH1 and prostate cancer: We used a SUVmax increase above 30% to define a non-responding lesion, adopted from the PSMA PET Progression criteria (PPP) and the consensus statements on PSMA-PET/CT response assessment criteria in prostate cancer (Fanti et al. 2020, 2021) as well as volume cut-offs defined in the RECIP framework (Gafita et al. 2022) to evaluate lesion response to MDT on PMSA-PET/CT.